Direkt zum Inhalt
Merck
  • The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia.

The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia.

Physiological research (2015-10-09)
J Sirc, J Hrib, M Vetrik, R Hobzova, A Zak, B Stankova, O Slanar, R Hromadka, V Sandrikova, J Michalek
ZUSAMMENFASSUNG

Hyperlipidemia treatment based on niacin requires gastrointestinal administration of relatively high doses. The recommended dietary allowance of niacin as vitamin B3 is 14 to 16 mg daily in adults, while the doses of niacin used in the treatment of hyperlipidemia are generally in the range of 1 to 3 g. Administration of such large doses requires a high concentration of the active compound in the tablet and proper control of the drug release. In this study, a hydrogel matrix based on poly(2-hydroxyethyl methacrylate) and polyvinylpyrrolidone was investigated as delivery vehicle for controlled NA release into the gastrointestinal environment. The prepared hydrogel matrices varied in used monomer and crosslinker types and concentrations. The content of NA in tablets was between 65-80 %. The release profiles of NA from tablets were examined under three different pH values (1, 4.5 and 6.8) over the time period of 30 h. The effects of the monomer ratio, the crosslinking of the polymer network, and the solubility of niacin during drug release under various pH are discussed. The results showed that the release time period can be achieved in a relatively wide range of time and can be adjusted according to the medical requirements.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Salzsäure, ACS reagent, 37%
Sigma-Aldrich
Salzsäure, ACS reagent, 37%
Sigma-Aldrich
Chlorwasserstoff -Lösung, 4.0 M in dioxane
Sigma-Aldrich
Salzsäure -Lösung, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
1-Vinyl-2-pyrrolidon, contains sodium hydroxide as inhibitor, ≥99%
Sigma-Aldrich
2,2′-Azobis(2-Methylpropionitril), 98%
Sigma-Aldrich
Salzsäure, meets analytical specification of Ph. Eur., BP, NF, fuming, 36.5-38%
Sigma-Aldrich
Salzsäure, 37 wt. % in H2O, 99.999% trace metals basis
Sigma-Aldrich
2-Hydroxyethylmethacrylat, ≥99%, contains ≤50 ppm monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
Chlorwasserstoff -Lösung, 2.0 M in diethyl ether
Sigma-Aldrich
Ethylenglykoldimethacrylat, 98%, contains 90-110 ppm monomethyl ether hydroquinone as inhibitor
Sigma-Aldrich
Salzsäure, 36.5-38.0%, BioReagent, Molecular Biology
Sigma-Aldrich
2-Hydroxyethylmethacrylat, contains ≤250 ppm monomethyl ether hydroquinone as inhibitor, 97%
Supelco
Salzsäure -Lösung, volumetric, 0.1 M HCl (0.1N), endotoxin free
Sigma-Aldrich
Nicotinsäure, ≥99.5% (HPLC)
Sigma-Aldrich
Chlorwasserstoff -Lösung, 1.0 M in diethyl ether
Sigma-Aldrich
Salzsäure -Lösung, ~6 M in H2O, for amino acid analysis
Sigma-Aldrich
Chlorwasserstoff, ReagentPlus®, ≥99%
Sigma-Aldrich
Nicotinsäure, ≥98%
Sigma-Aldrich
Chlorwasserstoff -Lösung, 3 M in cyclopentyl methyl ether (CPME)
Supelco
Nicotinsäure, analytical standard
Sigma-Aldrich
Nicotinsäure, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Salzsäure -Lösung, 32 wt. % in H2O, FCC
Sigma-Aldrich
Chlorwasserstoff -Lösung, 1.0 M in acetic acid
Sigma-Aldrich
2-Hydroxyethylmethacrylat
Sigma-Aldrich
Nicotinsäure, meets USP testing specifications